Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 24-32 , February 2010

Second-line treatment for malignant pleural mesothelioma

  • Giovanni Luca Ceresoli

      Affiliations

    • Department of Oncology, Istituto Humanitas Gavazzeni, Bergamo, Italy
    • Department of Oncology, Istituto Clinico Humanitas IRCCS, via A. Manzoni 59, 20089 Rozzano, Milan, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Oncology, Istituto Humanitas Gavazzeni, via M. Gavazzeni 21, 24125 Bergamo, Italy. Tel.: +39 035 4204 663; fax: +39 035 4204 303.
    • ,
  • Paolo Andrea Zucali

      Affiliations

    • Department of Oncology, Istituto Clinico Humanitas IRCCS, via A. Manzoni 59, 20089 Rozzano, Milan, Italy
    • Tel.: +39 02 8224 4080; fax: +39 02 8224 4090.
    • ,
  • Letizia Gianoncelli

      Affiliations

    • Department of Oncology, Istituto Clinico Humanitas IRCCS, via A. Manzoni 59, 20089 Rozzano, Milan, Italy
    • Tel.: +39 02 8224 4080; fax: +39 02 8224 4090.
    • ,
  • Elena Lorenzi

      Affiliations

    • Department of Oncology, Istituto Clinico Humanitas IRCCS, via A. Manzoni 59, 20089 Rozzano, Milan, Italy
    • Tel.: +39 02 8224 4080; fax: +39 02 8224 4090.
    • ,
  • Armando Santoro

      Affiliations

    • Department of Oncology, Istituto Clinico Humanitas IRCCS, via A. Manzoni 59, 20089 Rozzano, Milan, Italy
    • Tel.: +39 02 8224 4080; fax: +39 02 8224 4090.

Received 6 May 2009 ,Revised 23 September 2009 ,Accepted 25 September 2009.

References 

  1. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603
  2. Ceresoli GL, Gridelli C, Santoro A. Multisciplinary treatment of malignant pleural mesothelioma. Oncologist. 2007;12:850–863
  3. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556–1561
  4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  5. Hazarika M, White RM, Booth BP, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:982–992
  6. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24:1443–1448
  7. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19:370–373
  8. Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol. 2008;3:756–763
  9. Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, Van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5:136–147
  10. Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer. 1984;54:961–964
  11. Hoffman KR. Paclitaxel and carboplatin combination chemotherapy is an effective palliative treatment for malignant mesothelioma. Proc Am Soc Clin Oncol 1996;abstr. 1428.
  12. Vogelzang NJ. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?. J Clin Oncol. 1999;17:2626–2627
  13. Karthaus M, Frieler F, Plahl A, Wert N, Tagizadeh K, Metzner D. Second line chemotherapy for patients with malignant mesothelioma (MPM) pretreated with pemetrexed and platinum. In: 2005 ASCO annual meeting proceedings, J Clin Oncol 2005;23(16S, Part I of II (June 1 Supplement)):7331.
  14. Giaccone G, O’Brien MER, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer. 2002;38(Suppl. 8):19–24
  15. Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005;48:429–434
  16. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003;21:349–354
  17. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin and mitomycin in mesothelioma. Cancer. 2007;109:93–99
  18. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–152
  19. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18:3912–3917
  20. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63:94–97
  21. Sørensen JB, Sundstrom S, Perell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol. 2007;2:147–152
  22. Jänne PA, Wozniak AJ, Bellini CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–512
  23. Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program. J Thorac Oncol. 2008;3:761–764
  24. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–1704
  25. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16:923–927
  26. Razak AR, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer. 2008;60:294–297
  27. Serke M, Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesotelioma. In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007;25(18S (June 20 Supplement):18198.
  28. De Vincenzo F, Zucali PA, Ceresoli GL, et al. Re-treatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 163.
  29. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schonfeld N, Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 2008;18:3(1):34 [Epub ahead of print].
  30. Zucali PA, Ceresoli GL, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer. 2008;112:1555–1561
  31. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006;42:2706–2714
  32. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999;81:54–61
  33. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–475
  34. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007:25(18S (June 20 Supplement)):7526.
  35. Ceresoli GL, Zucali PA, De Vincenzo F, et al. Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM). In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 11.
  36. Kindler HL, Vogelzang NJ, Chien K, et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001:20(abstr. 1359).
  37. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, Van Zandwijk N. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer. 2005;48:291–296
  38. Pavlakis N, Abraham R, Harvie R, et al. Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma (MM): interim results from two parallel non randomized phase II studies. Lung Cancer 2003;41(Suppl. 2):S11, abstr. O-26. Abstract of the 10th world conference on lung cancer.
  39. Dowell JE, Kindler HL. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin N Am. 2005;19:1137–1145
  40. Janne PA, Wang XF, Krug LM, Hodgson L, Vokes EE, Kindler HL. Sorafenib in malignant pleural mesothelioma (MM): a phase II trial of the Cancer and Leukemia Group B (CALGB 30307). In: 2007 ASCO annual meeting proceedings Part I, J Clin Oncol 2007:25(18S (June 20 Supplement)):7707.
  41. Nowak A, Millward M, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 116.
  42. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–260
  43. Francis RJ, Byrne MJ, Van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48:1449–1458
  44. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18-F fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–4593
  45. Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. Curr Oncol. 2007;14:154–161
  46. Garland LL, Chansky K, Wozniak A, et al. SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 2009;27:15s (Suppl; abstr. 7511).
  47. Schiller JH, Storer BE, Witt PL, et al. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res. 1991;51:1651–1658
  48. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185–1190
  49. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest. 2002;110:475–482
  50. Zucali PA, Gregorc V, Ceresoli GL, et al. NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): preliminary results of a multicenter phase II trial. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 10.
  51. Edwards JG, Cox G, Andi A, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 2001;85:863–868
  52. Arber D, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD 117) in human tissue: value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498–504
  53. Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer. 2005;50:83–86
  54. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2007;59:149–150
  55. Millward M, Parnis F, Byrne M, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003;22:228S (abstr. 912).
  56. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL. A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). In: 2004 ASCO annual meeting proceedings (post-meeting edition), J Clin Oncol 2004:22(14S (July 15 Supplement)):7200.
  57. Edwards JG, Swinson DEB, Jones JL, Waller DA, O’Byrne KJ. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer. 2006;54:399–407
  58. Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer. 2006;51:207–215
  59. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor signalling in malignant pleural mesothelioma. Cancer Res. 2002;62:5242–5247
  60. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113:808–814
  61. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:2300–2304
  62. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007;25:2406–2413
  63. Cortese JF, Gowda AL, Wali A, Eliason JF, Pass HI, Everson RB. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer. 2006;118:521–522
  64. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–5552
  65. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21:427–436
  66. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4:97–101
  67. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesotelioma. Biologics. 2008;2:601–609
  68. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002;20:274–281
  69. Reck M, Krzakowski M, Jassem J, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). J Clin Oncol 2009;27:15s (Suppl; abstr. 7507).
  70. Scagliotti GV, Selvaggi G. Emerging drugs for mesothelioma. Expert Opin Emerg. Drugs. 2007;12:127–137
  71. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62:4645–4655
  72. Ogino H, Yano S, Kakiuchi S, et al. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Cancer Lett. 2008;265:55–66
  73. Betta PG, Castagneto B, Libener R, et al. The tyrosine kinase inhibitor ZD6474 inhibits cell proliferation and induces apoptosis in malignant mesothelioma. Ann Oncol 2006;17(Suppl. 9):ix57, abstr. 92PD.
  74. www.clinicaltrials.gov; A randomized Phase II trial to evaluate the efficacy and safety of Vandetanib (ZD6474, ZACTIMA™) versus vinorelbine in patients with inoperable or relapsed malignant mesothelioma; NCT00597116.
  75. Atkins MB, Yasotan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov. 2009;8:535–536
  76. O’Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26:1588–1595
  77. www.clinicaltrials.gov; Phase II trial of mTOR inhibitor, Everolimus (RAD001), in malignant pleural mesothelioma (MPM); NCT00770120.
  78. Sartore-Bianchi A, Gasparri F, Galvani A, et al. Bortezomib inhibits nuclear factor-kB-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res. 2007;13:5942–5951
  79. Gordon GI, Mani M, Maulik G, et al. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008;61:549–558
  80. www.clinicaltrials.gov; An open label phase II multicentre clinical trial of single agent bortezomib in patients with malignant pleural mesothelioma; NCT00513877.
  81. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257–261
  82. www.clinicaltrials.gov; A phase III, randomized, double-blin, placebo-controlled trial of oral suberoylanilide hydroxamic acid (SAHA) in patients with advanced malignant pleural mesothelioma previously treated with systemic chemotherapy; NCT00128102.
  83. Krug LM, Marangolo M, Kindler HL, et al. A phase III, randomized, double-blind, placebo-controlled trial of vorinostat in patients with (MPM) previously treated with systemic chemotherapy. In: Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group), Amsterdam (The Netherlands) 2008;abstr. 223.
  84. Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma therapy: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007;62:690–695
  85. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res. 2008;14:541–548
  86. Ali Y, Lin Y, Gharibo MM, et al. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5876–5882
  87. www.clinicaltrials.gov; A Phase II study of the association of Glivec® plus Gemzar® in patients with unresectable, refractory, malignant mesothelioma; NCT00551252.
  88. Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007;6:1962–1972
  89. www.clinicaltrials.gov; A phase II study of Dasatinib (NSC #732517) in patients with previously treated malignant mesothelioma; NCT00509041.
  90. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008;44:46–53
  91. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–231
  92. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatments. J Clin Oncol. 2006;24:1770–1783
  93. Lopez-Rios F, Chuai S, Flores S, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970–2979
  94. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/Hepatocyte Growth Factor pathway in malignant pleural mesothelioma. Cancer Res. 2006;66:352–361
  95. Pollak M. Insuline and insuline-like growth factors signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928
  96. Whitson BA, Jacobson BA, Frizelle S, et al. Effects of insuline-like growth factor-1 receptor inhibition in mesothelioma. Ann Thorac Surg. 2006;82:996–1002

PII: S0305-7372(09)00141-8

doi: 10.1016/j.ctrv.2009.09.003

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 24-32 , February 2010

Article Tools